Phase 2 Trial: Cytisine and ASA for Inflammation in Lifelong Smokers
Can quitting smoking and changing your diet really reduce lung inflammation?
A Phase 2 trial evaluates cytisine for smoking cessation and ASA for inflammation in 2000 lifelong smokers.
Quitting smoking, eating better, and moving more can reduce lung inflammation in lifelong smokers, offering a path to breathe easier and low…
Hyper-oncotic Albumin Reduces Mortality in ARDS Compared to Crystalloid
Could hyper-oncotic albumin save lives in patients with severe lung issues?
Meta-analysis shows hyper-oncotic albumin reduces mortality in ARDS (OR=0.61, CI 0.43-0.85) vs. crystalloid. RCTs show no benefit.
Patients with severe lung issues had lower death rates when given hyper-oncotic albumin instead of standard fluids, though results varied by…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.
A new trial tests if adding targeted liver radiation to standard drugs helps metastatic lung cancer patients live longer without disease pro…